Otsuka and Lundbeck initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe (150KB)

Establishment of Joint Venture Company (Subsidiary) in India (121KB)

Otsuka Medical Devices and Pioneer Form
an Alliance in the Medical Endoscope Business (411KB)

Otsuka announces 2012 third quarter U.S. net sales figures of ABILIFY® (131KB)

Otsuka and Lundbeck Announce U.S. Food and Drug Administration Acknowledges Receipt of Resubmission of New Drug Application for Aripiprazole Depot Formulation (145KB)

ABILIFY®,The First Antipsychotic Agent in Japan
Applying for Adjunctive Treatment in Major Depressive Disorder (156KB)

Otsuka Holdings Announces Completion of Share Repurchase (83KB)

OTSUKA RECEIVES COMPLETE RESPONSE LETTER FOR EXTENDED-RELEASE INJECTABLE SUSPENSION OF ARIPIPRAZOLE (127KB)

Otsuka announces 2012 second quarter U.S. net sales figures of ABILIFY® (126KB)

Otsuka Holdings Announces Personnel Changes (Resignation) of Representative Director (84KB)

Notice regarding Status of Acquisition of Own Shares (111KB)

Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology (175KB)

Notice of the Result of Share Repurchase through ToSTNeT-3 (82KB)

Notice of Acquisition of Own Shares through ToSTNeT-3 (83KB)

Otsuka Holdings Co., Ltd. to Acquire Own Shares (102KB)

Otsuka Holdings Announces Personnel Changes (180KB)

RESULTS FROM A PHASE 3 STUDY OF ONCE-MONTHLY ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT FORMULATION FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA PRESENTED AT APA ANNUAL MEETING (197KB)

Otsuka announces 2012 first quarter U.S. net sales figures of ABILIFY® (126KB)

Otsuka America Announces Personnel Changes (182KB)

Otsuka announces 2011 fourth quarter U.S. net sales figures of ABILIFY® (58KB)

Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets" (267KB)

Otsuka Pharmaceutical and UCB
focus collaboration in the area of Central Nervous System (CNS) disorders (51KB)